Objective:

The article examines the objective, findings, and clinical context described in FDA tentatively approves generic lenacapavir.

Approach:

• Regulatory status: The FDA granted tentative approval under its international HIV drug review program. This does not authorize US marketing while applicable patent protections remain in effect.
• Product and access: The twice-yearly injection is intended to reduce sexually acquired HIV-1 risk in adults and adolescents weighing at least 35 kg. CHAI reported an annual price of $40 per person; Unitaid reported the initial oral loading course costs up to $17.
• Development pathway: Dr. Reddy’s developed the generic with financial, technical, and regulatory support from CHAI, Unitaid, and Wits RHI. CHAI said the application combined treatment and prevention indications through the FDA’s 505(b)(2) pathway.

Key Findings:

• CHAI said tentative approval may help accelerate national regulatory reviews in 120 low- and middle-income countries.
• CHAI expected initial supplies before year-end and broader availability in 2027; access will depend on procurement, funding, and distribution.
• In PURPOSE 1, no infections occurred among 2,134 participants receiving the original lenacapavir formulation, compared with 16 among 1,068 receiving daily emtricitabine/tenofovir disoproxil fumarate.
• In PURPOSE 2, infections occurred in 2 of 2,179 participants receiving lenacapavir and 9 of 1,086 receiving the oral comparator. Lenacapavir reduced incidence by 96% versus estimated background incidence and 89% versus daily oral PrEP.
• The PURPOSE trial results concern Gilead’s original formulation, not a separate efficacy trial of Dr. Reddy’s generic.

Interpretation:

The tentative approval is not US marketing authorization. Gilead’s branded lenacapavir (Yeztugo) remains patent-protected in the United States. The cited prevention efficacy results are from trials of the original formulation.

Limitations:

• The context provides no separate efficacy trial results for Dr. Reddy’s generic.
• The timing and reach of access depend on procurement, funding, and distribution arrangements.
• Lenacapavir labeling includes a boxed warning about drug resistance in people with undiagnosed HIV-1 infection and requires HIV testing before initiation and before each subsequent injection.

Conclusion:

The FDA’s tentative approval may support regulatory review and access planning in participating countries, while patent protections prevent US marketing at this time.

Sources:

• Clinton Health Access Initiative
• Unitaid
• NEJM, PURPOSE 1
• NEJM, PURPOSE 2
• DailyMed
• FDA PEPFAR FAQs
• FDA PDUFA V Fee Information